Which stories, features and interviews captured the attention of the cardiovascular community across 2024? Read our summary of the trending stories from across the Cardiovascular News network throughout the year.
The cardiology world mourned the loss of Alain Cribier, the pioneering cardiologist who performed the world’s first transcatheter aortic valve implantation (TAVI) in 2002, who died in February at the age of 79. He was described as “a true visionary” whose life and work “stand as a testimony to all that is good in medicine”.
Past, present and future of cardiovascular innovation celebrated at Global Cardiovascular Awards
Winners of the first annual Global Cardiovascular Awards, hosted by Cardiovascular News, were announced at an exclusive ceremony in March. Alain Cribier, the founding father of TAVI, was posthumously recognised for his role in advancing the field of cardiovascular care, winning the Lifetime Achievement award, whilst winners across 12 other categories were named.
Johnson & Johnson to acquire Shockwave Medical
Johnson & Johnson announced the proposed acquisition of Shockwave Medical, a provider of intravascular lithotripsy (IVL) technology, in April, with the deal ultimately completing in May.
Settling the paclitaxel versus sirolimus DCB debate
Bernardo Cortese (Fondazione Ricerca e Innovazione Cardiovascolare, Lodi, Italy and DCB Academy) a leader in research on drug-coated balloons (DCBs) in percutaneous coronary intervention (PCI) writes for Cardiovascular News about the paclitaxel versus sirolimus debate.
Radiofrequency renal denervation meets cost efficiency threshold in value analysis
An analysis of data from the SPYRAL HTN-ON MED trial of the Symplicity Spyral (Medtronic) radiofrequency denervation system for the treatment of uncontrolled hypertension has found that the technique can be expected to provide “good value for money” as a therapeutic approach.
Analysis of one-year results from the NOTION-2 trial, in which investigators compared transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) in younger, low-risk patients, point towards less favourable outcomes after TAVI in patients with bicuspid aortic stenosis.
EACTS and STS guidelines recognise aorta “as an organ in its own right”
New guidelines from the European Association for Cardio-Thoracic Surgery (EACTS) and the Society of Thoracic Surgeons (STS) have, for the first time, recognised the aorta as “an organ in its own right”.
Adjustable valve replacement system wins TCT Shark Tank innovation prize
Symbiosis, the developer of an adjustable transcatheter mitral valve replacement (TMVR) system—Valsync—has been chosen as the recipient of the Shark Tank innovation prize at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) conference (27–30 October, Washington, DC, USA).
Data show shift in the proportion of patients under 60 receiving TAVI instead of SAVR
Research presented at the 60th annual meeting of the Society of Thoracic Surgeons (STS 2024; 27–29 January, San Antonio, USA) shows a shift in the proportion of patients aged under 60 years with severe aortic stenosis, eligible for surgical aortic valve replacement (SAVR), who are receiving transcatheter aortic valve implantation (TAVI).
Results of the SMART trial, comparing the use of two widely deployed transcatheter aortic valve implantation (TAVI) systems in patients with small aortic annuli, has found that the use of a supra-annular self-expanding valve resulted in similar clinical outcomes and superior valve performance at one year compared with a balloon-expandable valve.
